PGP and uterine corpus sarcoma: Thus, a model of cells resistant to Dox by overexpression of P-gp protein was developed in uterine sarcoma, MES-SA/Dx5 cells [30], and for which, according to the literature, we have not observed cross-chemoresistance with other classical anticancer agents (Figure 1, Table 1).